Pi*S and Pi*Z alpha 1 antitrypsin polymorphism and the risk for asbestosis in occupational exposure to asbestos

Toxicology Letters

Volumn 136, Issue 1, 2002, Pages 9-17

  Lafuente, M J ^a   Casterad, X ^a   Laso, N ^a   Mas, S ^a   Panades, R ^b   Calleja, A ^b   Hernandez, S ^b   Turuguet, D ^b   Ballesta, A ^c   Ascaso, C ^a   Lafuente, A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Center for Safety and Health Conditions at Work   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Alpha 1 antitrypsin; Asbestosis; Occupational exposure; Polymorphism; Susceptibility genes

Indexed keywords

ALPHA 1 ANTITRYPSIN; ASBESTOS; DNA; ISOENZYME; PANCREATIC ELASTASE;

ADULT; AGE; AGED; ARTICLE; ASBESTOSIS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCUPATIONAL EXPOSURE; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SMOKING HABIT; WORKER; ALLELE; ANALYSIS OF VARIANCE; ENZYMOLOGY; FOLLOW UP; GENETICS; LUNG; LUNG FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SMOKING; SPAIN;

ADULT; ALLELES; ALPHA 1-ANTITRYPSIN; ANALYSIS OF VARIANCE; ASBESTOS; ASBESTOSIS; DNA; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; ISOENZYMES; LUNG; MALE; MIDDLE AGED; OCCUPATIONAL EXPOSURE; PANCREATIC ELASTASE; POLYMORPHISM, GENETIC; RESPIRATORY FUNCTION TESTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; SMOKING; SPAIN;

EID: 18644375366     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-4274(02)00283-7     Document Type: Article

References (37)

1. Afanaseva I.S., Spitsyn V.A., Tsurikova G.V. The association of genetic and functional variability of alpha 1-antitrypsin in asbestosis. Genetika. 29:1993;1727-1732.
2. Agudo A., Gonzalez C.A., Bleda M.J., et al. Occupational and risk of malignant pleural mesothelioma: a case-control study in Spain. Am. J. Ind. Med. 37:2000;159-168.
3. Alonso A., Visedo G., Sancho M., et al. Isoelectric focusing in miniaturized gels: application to GC, PI, Tf and ORM subtyping in Central Spain. Polesky H.F., Mayr W.R., Advances in Forensic Haemogenetics. 3:1990;255-259 Springer, Berlin.
4. Benetazzo M.G., Gile L.S., Bombieri C., et al. Alpha 1-antitrypsin TAQ1 polymorphism and alpha 1-antichymotrypsin mutations in patients with obstructive pulmonary disease. Respir. Med. 93:1999;648-654.
5. Brantly M., Nukiwa T., Crystal R.G. Molecular basis of alpha1-antitrypsin deficiency. Am. J. Med. 84:1988;13-31.
6. Braun A., Meyer P., Cleve H., et al. Rapid and simple diagnosis of the two common a1- proteinase inhibitor deficiency alleles Pi*Z and Pi*S by DNA analysis. Eur. J. Clin. Chem. Clin. Biochem. 34:1996;761-764.
7. Caporaso N., Hayes R.B., Dosemeci M., et al. Lung cancer risk, occupational exposure, and the Debrisoquine metabolic phenotype. Cancer Res. 49:1989;3675-3679.
8. Clasificación Nacional de Actividades Económicas (CNAE-93), 1993. Real Decreto 1560/1992 de 18 de Diciembre. Boletin Oficial del Estado, BOE 22/12/1992.
9. Cocco P., Dosemici M. Peritoneal cancer and occupational exposure to asbestos: results from the application of a job-exposure matrix. Am. J. Ind. Med. 35:1999;9-14.
10. Crystal R.G. a1-antitrypsin deficiency, emphysema, and liver disease. Genetic basis and strategies for therapy. J. Clin. Invest. 85:1990;1343-1352.
11. Crystal R.G., Brantly M.L., Hubbard R.C., et al. The alpha1-antitrypsin gene and its mutations: clinical consequences and strategies for therapy. Chest. 95:1989;196-208.
12. 264-Val) mutation results from exaggerated preglycosylation intracellular degradation of alpha1antitrypsin prior to secretion. J. Biol. Chem. 264:1989;10477-10485.
13. Dirksen A., Dijkman J.H., Madsen F., et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am. J. Respir. Crit. Care Med. 160:1999;1468-1472.
14. Dry P.J. Rapid detection of alpha-1-antitrypsin deficiency by analysis of a PCR-induced TaqI restriction site. Hum. Genet. 87:1991;742-744.
15. Erren T.C., Jacobsen M., Piekarski C. Synergy between asbestos and smoking on lung cancer risks. Epidemiology. 10:1999;405-411.
16. Estefania F.J., Carracedo A., Pancorbo M. Alpha -1-antitrypsin (Pi) subtypes in Spanish Basque provinces. Hum. Hered. 37:1987;321-332.
17. Faber J.P., Poller W., Weidinger S., et al. Identification and DNA sequence analysis of 15 new alpha-1-antitrypsin variants, including two Pi*Q alleles and one deficient Pi*M allele. Am. J. Hum. Genet. 55:1994;1113-1121.
18. Gadek J.E., Zimmerman R.L., Fells G.A., et al. Antielastases of the human alveolar: structures implications for the protease-antiprotease theory of emphysema. J. Clin. Invest. 68:1981;889-898.
19. Hirvonen A., Pelin K., Tammilehto L., et al. Inherited GSTM1 and NAT2 defects as concurrent risk modifiers in asbestos-related human malignant mesothelioma. Cancer Res. 55:1995;2981-2983.
20. Hirvonen A., Saarikoski S.T., Linnainmaa K., et al. Glutathione S-transferase and N-acetyltransferase genotypes and asbestos-associated disorders. J. Natl. Cancer Inst. 88:1996;1853-1856.
21. Hutchison D.C. Alpha 1-antitrypsin deficiency in Europe: geographical distribution of Pi types S and Z. Respir. Med. 92:1998;367-377.
22. International Standard Classification of Occupations (ISCO) 1968. Revised edition. International Labour Office 1969, Geneva.
23. Jakobsson K., Rannug A., Alexandrie A.K., et al. Radiographic changes and lung function in relation to activity of the glutathione transferases theta and mu among asbestos cement workers. Toxicol. Lett. 77:1995;363-369.
24. Kelsey K.T., Nelson H.H., Wiencke J.K., et al. The glutathione S-transferase theta and mu deletion polymorphisms in asbestosis. Am. J. Ind. Med. 31:1997;274-279.
25. Kurachi K., Chandra T., Degen S.J.F., et al. Cloning and sequence of cDNA coding for alpha-1-antitrypsin. Proc. Natl. Acad. Sci. USA. 78:1981;6826-6830.
26. Lafuente M.J., Casterad X., Trias M., et al. NAD(P)H: quinone oxidoreductase-dependent risk for colorectal cancer and its association with the presence of K-ras mutations in tumors. Carcinogenesis. 21:2000;1813-1819.
27. Laurell C.B., Sveger T. Mass screening of newborn Swedish infants for a1-antitrypsin deficiency. Am. J. Hum. Genet. 27:1975;213-217.
28. Long G.L., Chandra T., Woo S.L.C., et al. Complete sequence of the cDNA for human alpha-1-antitrypsin and the gene for the S-variant. Biochemistry. 23:1984;4828-4837.
29. Magnani C., Agudo A., Gonzalez C.A., et al. Multicentric study on malignant pleural mesothelioma and non-occupational exposure to asbestos. Br. J. Cancer. 83:2000;104-111.
30. Mc Donald J.C. Mineral dusts and fibres. Mc Donald J.C., Epidemiology of Work-Related Diseases. 1995;87-116 BMJ Publishing Group, London.
31. McElvaney N.G., Crystal R.G. Clinical manifestations of a1.AT deficiency. Crystal R.G., Alpha1-Antitrypsin Deficiency. 1996;227-243 Marcel Dekker, New York.
32. Rocha J., Pinto D., Santos T.M., et al. Analysis of the allelic diversity of a (CA)n repeat polymorphism among alpha1-antitrypsin gene products from northern Portugal. Hum. Genet. 99:1997;194-198.
33. Rom W.N., Travis W.D., Brody A.R. Cellular and molecular basis of the asbestos-related diseases. Am. Rev. Respir. Dis. 143:1991;408-422.
34. .Saarikoski S.T., Reinikainen M., Anttila S., et al. Role of NAT2 deficiency in susceptibility to lung cancer among asbestos-exposed individuals. Pharmacogenetics. 10:2000;183-185.
35. Smith C.M., Kelsey K.T., Wiencke J.K., et al. Inherited glutathione S-transferase deficiency is a risk factor for pulmonary asbestosis. Cancer Epidemiol. Biomark. Prev. 3:1994;471-477.
36. Wallace J.M., Oishi J.S., Barbers R.G., et al. Bronchoalveolar lavage cell and lymphocyte phenotype profiles in healthy asbestos-exposed shipyard workers. Am. Rev. Respir. Dis. 139:1989;33-38.
37. Wewers M.D., Casolaro M.A., Sellers S., et al. Replacement therapy for alpha 1-antitrypsin deficiency associated with emphysema. N. Engl. J. Med. 316:1987;1055-1062.